Balance Sheet Quoin Pharmaceuticals, Ltd.
Equities
QNRX
US74907L4095
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.72 USD | +14.07% |
|
-9.53% | -50.70% |
| 12-05 | Top Premarket Decliners | MT |
| 11-11 | Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies | CI |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
Assets | ||||||
Cash And Equivalents | 324K | 7.48M | 2.86M | 2.4M | 3.62M | |
Short Term Investments | - | - | 9.99M | 8.29M | 10.43M | |
Total Cash And Short Term Investments | 324K | 7.48M | 12.85M | 10.69M | 14.06M | |
Prepaid Expenses | - | 1.02M | 517K | 591K | 869K | |
Other Current Assets, Total | 141K | - | - | - | - | |
Total Current Assets | 465K | 8.5M | 13.37M | 11.29M | 14.93M | |
Other Intangibles, Total | 913K | 809K | 705K | 583K | 483K | |
Other Long-Term Assets, Total | - | 50K | 383K | 300K | 300K | |
Total Assets | 1.38M | 9.36M | 14.46M | 12.17M | 15.71M | |
Liabilities | ||||||
Accounts Payable, Total | - | 923K | 606K | 527K | 906K | |
Accrued Expenses, Total | 4.99M | 6.54M | 2.32M | 2.45M | 2.68M | |
Short-term Borrowings | 1.21M | - | - | - | - | |
Current Portion of Long-Term Debt | - | - | 600K | 600K | 600K | |
Other Current Liabilities | 1.78M | 865K | - | - | - | |
Total Current Liabilities | 7.99M | 8.33M | 3.53M | 3.58M | 4.18M | |
Long-Term Debt | - | - | 3.52M | 2.92M | 2.32M | |
Other Non Current Liabilities | - | 374K | - | - | - | |
Total Liabilities | 7.99M | 8.7M | 7.05M | 6.51M | 6.5M | |
Common Stock, Total | 100 | - | - | - | - | |
Additional Paid In Capital | - | 31.66M | 47.86M | 51.87M | 64.37M | |
Retained Earnings | -6.61M | -28.07M | -37.52M | -46.2M | -55.17M | |
Treasury Stock | - | -2.93M | -2.93M | - | - | |
Total Common Equity | -6.61M | 657K | 7.41M | 5.66M | 9.2M | |
Total Equity | -6.61M | 657K | 7.41M | 5.66M | 9.2M | |
Total Liabilities And Equity | 1.38M | 9.36M | 14.46M | 12.17M | 15.71M | |
Supplemental Items | ||||||
ECS Total Shares Outstanding on Filing Date | 28.57K | - | 28.21K | 105K | 588K | |
ECS Total Common Shares Outstanding | 28.57K | - | 11.54K | 28.21K | 256K | |
Book Value / Share | -231.26 | - | 641.72 | 200.81 | 36 | |
Tangible Book Value | -7.52M | -152K | 6.7M | 5.08M | 8.72M | |
Tangible Book Value Per Share | -263.2 | - | 580.68 | 180.13 | 34.11 | |
Total Debt | 1.21M | 0 | 4.12M | 3.52M | 2.92M | |
Net Debt | 889K | -7.48M | -8.73M | -7.17M | -11.13M | |
Debt Equivalent Oper. Leases | 1.57K | - | - | - | - | |
Account Code - Inventory Valuation | 3 | 3 | 3 | 3 | 3 | |
Full Time Employees | 2 | 4 | 4 | 4 | 3 | |
Part Time Employees | - | - | - | - | 2 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















